MIRA Pharmaceuticals Inc

MIRA Pharmaceuticals Inc operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.0 and no long-term debt. The company's liquidity position is strong, with a current ratio of 5.7, indicating that it holds significantly more current assets than current liabilities. However, the company's operating cash flow is negative at -$1,049,540, which suggests ongoing cash burn and a lack of positive cash generation from operations. Profitability metrics for MIRA are negative, with a return on equity (ROE) of -54.42% and a return on assets (ROA) of -45.1%. These figures are well below the typical thresholds for healthy performance in the biotechnology and medical research industry, where ROE and ROA are often used as key performance indicators. The company reported a net loss of -$1,717,770 and an operating loss of -$1,768,190, indicating that it is not yet generating profits from its core operations. MIRA's revenue is reported as $0, which suggests that the company is in the early stages of commercialization or is primarily focused on research and development. There is no geographic breakdown provided in the available data, but the absence of revenue implies that the company is not yet generating income from product sales in any region. The company's total assets amount to $3,808,790, with total equity of $3,156,790, indicating that the company is funded through equity rather than debt. The company's growth trajectory is currently negative, with no revenue reported and a net loss in the most recent period. Analysts have not provided revenue estimates, and the company's operating cash flow is negative, suggesting that it is not yet on a path to profitability. The lack of revenue and ongoing losses indicate that MIRA is in a pre-revenue or early-stage development phase, which is common for biotechnology firms. Risk factors for MIRA include the absence of positive cash flow from operations and the lack of revenue, which could lead to liquidity constraints if the company is unable to secure additional financing. The company's dilution risk is currently low, as there are no immediate filing-based liquidity or dilution flags. However, the company's reliance on equity financing could increase the risk of dilution in the future if it needs to raise additional capital to fund operations. Recent events for MIRA include the absence of disclosed revenue and the continuation of operating losses. The company has not filed any recent earnings reports or transcripts that would provide insight into its operational performance or strategic direction. The lack of revenue and ongoing losses suggest that the company is still in the development phase and has not yet commercialized any products.